Physiomics PLC Share Price Movement (7779T)
22 Julio 2020 - 5:45AM
UK Regulatory
TIDMPYC
RNS Number : 7779T
Physiomics PLC
22 July 2020
22 July 2020
Physiomics plc
("Physiomics") or ("the Company")
Share Price Movement
The Board of Physiomics plc (AIM: PYC), a provider of
technology-based solutions to predict the effects of cancer
treatment regimens for the biopharma industry, notes the recent
rise in the Company's share price and trading volumes and advises
the market that it knows of no specific reason for such significant
movements.
Further to its announcements of 27 May 2020 and 30 June 2020,
the Company remains in the late stages of finalising a contract
with the potential new large pharmaceutical client. While there is
no guarantee that the contract will be entered into, the commercial
terms have been agreed and the directors are confident it will be
signed in the coming weeks. Should the contract be entered into,
the project would take two of our technical staff around five
months to complete. Further updates will be provided as and when
appropriate in due course.
This announcement is released by Physiomics plc and contains
inside information for the purposes of Article 7 of the Market
Abuse Regulation (EU) 596/2014 (MAR), and is disclosed in
accordance with the Company's obligations under Article 17 of
MAR.
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Strand Hanson Ltd (NOMAD)
Richard Tulloch & James Dance
+44 (0)20 7409 3494
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0)20 3764 2341
Notes to Editor
About Physiomics
Physiomics(R) is an oncology consultancy using mathematical
models and its Virtual Tumour(TM) technology to support the
development of cancer treatment regimens and personalised medicine
solutions. The predictive capability of Virtual Tumour has been
confirmed by 55 projects, involving over 25 targets and 60 drugs,
and has worked with clients such as Merck KGaA, Merck & Co,
Bayer and Lilly.
Based in Oxford UK, the Company works with clients worldwide to
support their pre-clinical and clinical oncology development
programs. Its team of scientists and computer modelling experts
provide bespoke solutions encompassing data, analytics and
insight.
Physiomics senior management has academic and commercial
expertise, including over 90 years collectively of working in
oncology and/or computational biology and over 100 publications in
peer reviewed journals.
For more information please visit:
www.physiomics-plc.com
www.twitter.com/Physiomics
www.linkedin.com/company/physiomics-plc/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
SPMFLFSIDIIFFII
(END) Dow Jones Newswires
July 22, 2020 06:45 ET (10:45 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024